Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.78 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.69 |
| ▸ | FXR2 | P51116 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087810 | 1.00 | NR1H4 (0.78) | NR1H4HSD17B13FXR2 | |
| SCHEMBL14642052 | 1.00 | NR1H4 (0.78) | NR1H4HSD17B13FXR2 | |
| SCHEMBL15929549 | 0.96 | NR1H4 (0.72) | NR1H4HSD17B13 | |
| SCHEMBL15929531 | 0.96 | NR1H4 (0.72) | NR1H4HSD17B13 | |
| SCHEMBL17087813 | 0.91 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL14641899 | 0.91 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL14641893 | 0.91 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL15929526 | 0.89 | NR1H4 (0.70) | NR1H4HSD17B13 | |
| SCHEMBL15929519 | 0.89 | NR1H4 (0.75) | NR1H4HSD17B13FXR2 | |
| SCHEMBL19620265 | 0.89 | NR1H4 (0.75) | NR1H4HSD17B13FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| US-20210085662-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING PERSISTENCE AND EXPRESSION OF EPISOMAL VIRUSES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-25 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
| US-10745427-B2 | Acyclic antivirals | Janssen Biopharma, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-16 | — | — | US | disclosed |
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| US-9820979-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2017-05-25 | — | — | US | disclosed |
| WO-2017078928-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| EP-2987532-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| EP-2987532-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2731676-B1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2016-02-03 | — | — | EP | disclosed |
| WO-2015138986-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2013007387-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2013-01-17 | — | — | WO | disclosed |
| EP-2545964-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | Phenex Pharmaceuticals AG (DE) | 2013-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | NR1H4 672/4885HSD17B13 1244/4885FXR2 1446/4885 |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | PNP, TYMP, HAVCR2 | NR1H4 211/4885HSD17B13 637/4885FXR2 1560/4885 |
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 360/4885FXR2 5/4885 |
| US-20210085662-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING PERSISTENCE AND EXPRESSION OF EPISOMAL VIRUSES | NR1H4, ABCB11, FXR1 | NR1H4 1/4885HSD17B13 846/4885FXR2 6/4885 |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
| US-20190055273-A1 | ACYCLIC ANTIVIRALS | PNP, TYMP, DUT | NR1H4 602/4885HSD17B13 1624/4885FXR2 1259/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | NR1H4 672/4885HSD17B13 1244/4885FXR2 1446/4885 |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885HSD17B13 573/4885FXR2 2/4885 |
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | TYMP, POLB, HMBS | NR1H4 153/4885HSD17B13 173/4885FXR2 930/4885 |
| US-10745427-B2 | Acyclic antivirals | PNP, DUT, TYMP | NR1H4 672/4885HSD17B13 1244/4885FXR2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.